deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06347133

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

Sponsor: Arrowhead Pharmaceuticals

Updated 13 times since 2024 Last updated: Oct 3, 2025 Started: May 21, 2024 Primary completion: May 31, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertriglyceridemia and is currently ongoing. Arrowhead Pharmaceuticals leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshotRecruiting~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Aug 2025 · 4 months · monthly snapshotRecruiting~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshotActive Not Recruiting

Change History

13 versions recorded
  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  5. Apr 2025 — Aug 2025 [monthly]

    Recruiting PHASE3

Show 8 earlier versions
  1. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE3

  2. Dec 2024 — Mar 2025 [monthly]

    Recruiting PHASE3

  3. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE3

  4. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

  6. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  7. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  8. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arrowhead Pharmaceuticals
Data source: Arrowhead Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .